Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-20.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -83.26% |
| Return on Assets (Trailing 12 Months) | -70.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.42 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 10.78M |
| Free Float | 10.00M |
| Market Capitalization | $33.76M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 1.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.31% |
| Percentage Held By Institutions (Latest 13F Reports) | 28.62% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |